In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From CareDx, Inc.

Deals Shaping the Medical Industry, October 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.

Deals BioPharmaceutical

Galen/Barr: Burying the Hatchet

After this summer's failed merger talks between the two companies, Galen's three-pronged deal with US-based generics play Barr Laboratories might be the next best thing for Galen investors. At little cost, the deal removes much of the risk associated with the Northern-Irish company's legal battles. And even though agreements between branded players and their generics competitors often raise eyebrows at antitrust authorities, this deal's structure and focus on the heavily genericized oral contraceptives market may get it past the regulators.

BioPharmaceutical Europe

A Precarious Union: Combining Proprietary and Generic Businesses

The major generics companies, flush with cash from the recent plethora of patent expirations, are all forging ahead in the proprietary business in order to boost margins and even out the volatile revenues and earnings inherent in their core business. They're pursuing, by and large, strategies that don't take them far from their core expertise and involve reformulating known compounds. Some companies have had moderate success, but weaving together two such disparate businesses is a challenge.

BioPharmaceutical Strategy

FTC Boosts Generics, Bloodies Brands

Biovail's stock plummeted recently after a sell recommendation from a highly-regarded Wall Street analyst--who's been accused of a conflict of interest for issuing it--and an FTC ruling on its alleged anti-competitive practices. The ruling, on late-listed Orange Book entries, will curtain common anti-generic strategies.

BioPharmaceutical Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • XDx, ImmuMetrix, Inc.
UsernamePublicRestriction

Register